Dendritic Cell Vaccination in Treatment of Relapsed Pediatric AML
2 Views
administrator
07/04/23
Despite allogeneic hematopoietic cell transplantation the survival chances in pediatric AML are 50% only. With the developed adjuvant WT1 Cord Blood Derived Dendritic Cell Vaccine the survival chances may increase. The clinical study will start early 2017.
PIs: Dr Jaap Jan Boelens (clinical / translational) and Dr Stefan Nierkens (lab / translational)
Show more
Facebook Comments
No comments found